FUNDAMENTALS · Fundamentals · CN Healthcare

Consun Pharmaceutical Group (1681) Fundamentals 2026 — P/E 9.1x, Revenue Analysis | SniperIQ

Consun Pharmaceutical Group (1681) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of HK

1.2B, trading at HK
3.40 on the HKSE. This SniperIQ fundamentals page covers Consun Pharmaceutical Group's valuation (P/E 9.1x, P/B 2.2x), profitability (net margin 31.5%), revenue (¥3.4B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapHK
1.2B
P/E (TTM)9.1x
Net Margin31.5%
Revenue (FY25)¥3.4B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Consun Pharmaceutical Group's market cap?

Consun Pharmaceutical Group (1681) has a market capitalization of approximately HK

1.2B, trading at HK
3.40 on the HKSE. Market cap moves with the live share price.

What is Consun Pharmaceutical Group's P/E ratio?

Consun Pharmaceutical Group's trailing twelve-month P/E ratio is 9.1x, with a price-to-book (P/B) of 2.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Consun Pharmaceutical Group?

Consun Pharmaceutical Group runs a net profit margin of 31.5%, a gross margin of 78.0%, and an operating margin of 35.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Consun Pharmaceutical Group generate?

Consun Pharmaceutical Group reported revenue of ¥3.4B for fiscal year 2025, with net income of ¥1.1B and earnings per share (EPS) of 1.27. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Consun Pharmaceutical Group pay a dividend?

Consun Pharmaceutical Group offers a trailing dividend yield of about 5.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is Consun Pharmaceutical Group financially healthy?

Consun Pharmaceutical Group carries a debt-to-equity ratio of 0.05x and a current ratio of 3.22x, with a market beta of 0.46. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Consun Pharmaceutical Group a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Consun Pharmaceutical Group (1681) the key facts are: market cap HK

1.2B, P/E 9.1x, revenue ¥3.4B, 52-week range 12.31-19.35. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Consun Pharmaceutical Group's full fundamentals live

Get Consun Pharmaceutical Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: BioMarin Pharmaceutical (BMRN) fundamentals · Bio-Techne (TECH) fundamentals · Standard Chem & Pharm (1720) fundamentals · RaQualia Pharma (4579) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons